Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:
- an article about a $948 million patent infringement verdict between Intel and VLSI Technology LLC;
- another article about a Federal Circuit decision finding a generic cancer drug infringes on “Abbvie’s Pharmacyclics and Johnson & Johnson’s Janssen Biotech . . . blockbuster cancer drug Imbruvica”; and
- a blog post about a Federal Circuit decision affirming the Patent Trial and Appeal Board’s decision “involving American National Manufacturing and Sleep Number Corp.”
Michael Shapiro wrote an article for Bloomberg Law about a $948 million verdict reached by jurors in Austin, Texas. The jurors found that Intel “infringed on a VLSI patent designed to improve computer processor performance.” Shapiro reported that this is just “the latest chapter in [VLSI Technology LLC v. Intel Corp. ’s] sprawling intellectual property feud,” with “Judge Alan D. Albright of the US District Court for the Western District of Texas presiding over all three trials.”
Dani Kass authored an article for Law360 about a Federal Circuit decision finding a generic cancer drug infringes patents on “Abbvie’s Pharmacyclics and Johnson & Johnson’s Janssen Biotech . . . blockbuster cancer drug Imbruvica.” Kass reported that, in the case Pharmacyclics LLC v. Alvogen, Inc., the Federal Circuit found “Alvogen Inc. and Natco Pharma Ltd. can’t jump on the market before the patents expire to compete with Imbruvica.” Kass highlighted that Imbruvica “brought in more than $4 billion in revenue in 2021.”
Eileen McDermott wrote a blog post about a Federal Circuit decision affirming the Patent Trial and Appeal Board’s decision “involving American National Manufacturing and Sleep Number Corp.” McDermott explained that the Federal Circuit agreed that “some, but not all, of the challenged claims not unpatentable.” McDermott also reported that the patents at issue “’describe systems and methods that purport to adjust the pressure in an air mattress “in less time and with greater accuracy” than previously known.’”